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A major complication of primary Sjögren’s syndrome (pSS) is development of mucosa
associated lymphoid tissue (MALT) B-cell lymphoma, particularly in salivary glands. These
lymphomas express FcRL4 and are characteristically associated with lymphoepithelial
lesions. Neoplastic B-cells may be derived from non-neoplastic glandular intraductal
B-cells, also virtually all expressing FcRL4. A characteristic feature of MALT lymphomas
is the production of rheumatoid factors (RFs), which are largely encoded by stereotypic
immunoglobulin variable heavy chain (IGHV) sequences. The aim of this study was to
examine whether there is a relationship between the intraductal and periductal B-cells
and whether the intraductal B-cells are selected for RF. RNA was extracted from
laser-microdissected infiltrated ductal areas and periductal infiltrates from frozen parotid
gland tissue sections of 5 pSS patients. PCR amplified IGHV transcripts were cloned
into pCRTM4-TOPO vector and subsequently sequenced. Microdissected ducts yielded
96 unique IGHV sequences derived from intraductal B-cells, while 119 unique IGHV
sequences were obtained from periductal infiltrates. No major difference in VH-gene
usage was observed between intraductal and periductal B-cells. Nearly all (>90%)
IGHV sequences derived from both intraductal and periductal B-cells were mutated.
Clonal expansions as defined by shared VDJ rearrangements were also present among
both intraductal and periductal B-cells: in total 32 clones were found, from which 12
were located within ducts, 15 in periductal areas, and five clones shared members in
both areas. We observed 12 IGHV rearrangements encoding for RF sequences from
which two were derived from intraductal B-cells and 10 from periductal B-cells. Nine RF
sequences were part of a clone. Together these findings indicate that intraductal and
periductal B-cells are closely related to each other. Intraductal B-cells are most likely
derived from periductal B-cells. We did not obtain evidence that RF-specific B-cells
are enriched within the striated ducts. We speculate that in principle any activated
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B-cell can enter the striated ducts from the periductal infiltrate, irrespective of its
antigenic specificity. Within the ducts, these B-cells may receive additional activation and
proliferation signals, to further expand at these sites and by acquisition of driver-mutations
develop toward lymphoma.
Keywords: Sjögren’s syndrome, B-cells, FcRL4, IGHV repertoire, rheumatoid factor, salivary gland, parotid gland,
MALT lymphoma
INTRODUCTION
Primary Sjögren’s syndrome (pSS) is an autoimmune disease
primarily affecting the salivary and lacrimal glands resulting
in the characteristic complaints of dry mouth and dry
eyes. B-cell hyperactivity is a hallmark of this disease as,
amongst others, revealed by elevated levels of serum IgG and
free light chains, presence of rheumatoid factor (RF) and
anti-SSA/-SSB autoantibodies, and higher intrinsic levels of
Bruton’s tyrosine kinase (Btk), an enzyme critically involved
in B-cell receptor signaling (1–3). The B-cell hyperactivity
is also illustrated by the presence of clonal expansions of
B-cells in labial and parotid glands of pSS patients (4–
9). Chronic activation of B-cells probably also puts pSS
patients at a high risk of neoplastic transformation. In fact,
pSS patients have a 5–10% change of developing a non-
Hodgkin B-cell lymphoma (NHL), in particular parotid
gland mucosa-associated lymphoid tissue (MALT) B-cell
lymphoma (3, 10).
Histologically, infiltrates of B- and T-lymphocytes as well as a
wide variety of non-lymphoid cells, associated with the striated
ducts, are usually seen in the salivary glands of pSS patients
(11). Frequently the striated ducts comprise lymphoepithelial
lesions (LELs). LELs are composed of proliferative metaplastic
epithelial cells in combination with relative high numbers
of intraepithelial lymphocytes. Although both B- and T-
cells can be observed in the ductal epithelial layer, there
is evidence that B-cells in the ducts, here referred to as
intraductal B-cells, are involved in the formation of LELs (12).
Importantly, B-cell depletion therapy with rituximab of pSS
patients not only resulted in loss of B-cells from the ducts,
but concomitantly also in amelioration of the LELs (13). The
vast majority, if not all, B-cells within the LELs of both labial
and parotid salivary glands of pSS patients express inhibitory
Fc receptor-like protein 4 (FcRL4/IRTA1/CD307d) (14, 15). A
relative small number of B-cells in the periductal infiltrate
expresses FcRL4, and these cells are mostly located in close
proximity to the epithelium. The relationship between the
intraepithelial B-cells and the periductal B-cells is, however,
not known. A relative large fraction (>20%) of the intraductal
and a slightly smaller fraction of periductal FcRL4+ cells are
actively dividing cells, as reflected by Ki-67 expression (15).
Transcriptome analysis of FcRL4+ B-cells from parotid glands
of pSS patients (16) revealed that these FcRL4+ B-cells show
similarities in gene expression profile to chronically activated
CD11c+T-bet+ memory B-cells, which were shown to be
involved in the pathogenesis of systemic lupus erythematosus
(17, 18).
The notion that parotid MALT B-cell lymphomas of
pSS patients also express FcRL4, and that LELs are a
characteristic feature of salivary gland MALT lymphomas,
support the hypothesis that neoplastic MALT B-cells may arise
from glandular FcRL4+ intraductal B-cells (15). The recent
finding that several genes associated with lymphomagenesis are
upregulated in FcRL4+ B-cells (16), strengthens this hypothesis.
An important finding for MALT B-cell lymphomas is their
frequent expression of antibodies with RF activity (19, 20).
The transcripts of RF antibodies are frequently characterized
by specific immunoglobulin heavy chain variable gene (IGHV)
rearrangements. These rearrangements, result in amino acid
sequences of the IGHV-complementarity determining region 3
(CDR3) region with reactivity for IgG-Fc, so-called stereotypic
RF sequences (19, 21, 22). Although stereotypic RF sequences
have been observed in labial gland and parotid gland biopsies of
pSS patients, the proportion of these RF sequences is extremely
low (21, 23–25). It might, however, be that the (non-neoplastic)
FcRL4+ B-cells present in the striated ducts of non-lymphoma
pSS patients are enriched in RF producing cells. In this study
we therefore analyzed the IGHV repertoire of intraductal B-cells
and B-cells located in the periductal areas and analyzed their VH-
gene usage, mutation frequency, clonal expansion, and presence
of stereotypic RF sequences.
MATERIALS AND METHODS
Patients
Parotid gland biopsies of five patients fulfilling the ACR-
EULAR criteria for pSS (26) were included in this study. Patient
characteristics are summarized in Table 1. All patients were
female (median age 65 years, range 32–76 years). Four out of
five patients were seropositive for antibodies directed to anti-
Sjögren’s syndrome related antigen A (anti-SSA). These four were
also seropositive for RF. Biopsies were snap-frozen in liquid
nitrogen and cryopreserved at −80◦C until use. The biopsies
were without MALT lymphoma and had a Chisholm score
between 2 and 4. In parotid gland biopsies of four patients LELs
were present in the striated ducts. Usage of these biopsies for
research purposes was with approval from the medical ethical
committee of the University Medical Center of Groningen,
Groningen, the Netherlands (METc2013.066). All pSS patients
provided informed consent.
Laser Microdissection
Serial parotid gland cryosections of 9µm thickness, were
mounted on glass slides covered with polyethylene naphthalene-
membrane (MembraneSlide 1.0 PEN, Carl Zeiss Microscopy
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TABLE 1 | Characteristics of pSS patients.
Patient
biopsy
Gender M/F Age at biopsy SWS ml/min RF ANA Anti SSA Anti SSB Chisholm
score
GC LEL
pSS1 F 65 0.13 + + + + 4 − +
pSS2 F 67 0.43 + − + − 3 − +
pSS3 F 71 0.005 + + + + 4 − +
pSS4 F 38 0.43 − − − − 3 − -
pSS5 F 32 0.46 + + + x* 2 − +
SWS, stimulated whole saliva; RF, rheumatoid factor; ANA, antinuclear antibody; SSA, Sjögren’s-syndrome-related antigen A; SSB, Sjögren’s-syndrome-related antigen B; GC, germinal
center; LEL, lymphoepithelial lesion.
*x, data not available.
GmbH, Germany), fixed in acetone, stained with Mayer’s
hematoxylin, washed with diethyl pyrocarbonate-treated tap
water, dehydrated with alcohol and air dried. Periductal infiltrates
and striated ducts (with and without LELs) were microdissected
using a LMD6000 laser microdissection system (Leica, Wetzlar,
Germany). Ducts were taken from areas of the parotid
biopsy containing periductal infiltrates. Multiple microdissected
areas from serially cut periductal regions or striated ducts
of individual patients were pooled into the adhesive cap of
the collection tube (AdhesiveCap500, Carl Zeiss Microscopy
GmbH, Germany). After harvesting the microdissected areas,
65 µl lysis buffer (RNeasy Micro Kit; Qiagen, Leusden, The
Netherlands) was added and subsequently RNA was isolated. In
Supplementary Figure 2 we show an example of microdissected
striated ducts and periductal infiltrates.
RNA Isolation and cDNA Synthesis
Total RNA was extracted using the RNeasy Micro kit (Qiagen,
Leusden, The Netherlands), according to the manufacturer’s
protocol. cDNA was subsequently synthesized using Superscript
RT-III in a total volume of 20 µl containing 200 ng of random
hexamer primers (Invitrogen, Carlsbad, CA, USA), 20U RNase
inhibitor (Invitrogen), and 0.5mM dNTP (Invitrogen).
IGHV Gene Amplification and Cloning
Linear amplification of IGHV genes was based upon the
multiplex PCR of the Biomed-2 collaborative study (27)
using VH (1–6)-FR1 primers and the JH consensus primer
(Supplementary Table 1). cDNA was amplified in a total volume
of 50 µl Taq buffer (with KCl) containing 10 pmol of each
primer (Biolegio BV, Nijmegen, The Netherlands), 2mM of
each dNTP, 1.5mM Mg2Cl and 0.5U Taq DNA Polymerase
(Invitrogen). PCR products were gel-purified (PureLink R© Quick
Gel Extraction Kit (Invitrogen) before cloning into the pCRTM4-
TOPO vector (TOPO R©TA Cloning R©Kit for Sequencing,
Invitrogen). The recombinant vector was transformed into
chemically competent E. coli (One ShotTM TOP10, Invitrogen)
and grown in kanamycin selective LB medium. For each
transformation 50 colonies were randomly picked. Plasmids
were then isolated with the PurelinkTM96 Plasmid Purification
System, according to manufacturer’s protocol. Finally, IGHV
transcripts were sequenced (Macrogen Europe, Amsterdam,
The Netherlands).
Analysis of Rearranged Immunoglobulin
Genes
IGHV sequences were analyzed as described before (24). Briefly,
sequences were aligned with the human Ig set of the IMGT
reference directory (28). Only productive sequences, without
insertions and deletions, were included in this study. One
hundred percent identical IGHV sequences obtained from a
single biopsy were counted as one. Sequences with one or
more nucleotide difference were considered as unique sequences.
IGHV sequences using the same IGHV germline gene with
presence of shared mutations and (near-)identical amino acid
sequence at the CDR3 region, were considered clonally related.
RF Sequence Analysis
It has been shown that in ∼40 % of the salivary gland MALT
lymphomas cases, high-affinity stereotypic rheumatoid factor
(RF) B-cell receptors (BCR) have been found. The VH-CDR3
amino acid sequences of the BCRs show strong homology to
the VH-CDR amino acid sequence of RFs (19). Five groups
of stereotypic RFs have been described from which the VH-
CDR3 have been encoded by specific VDJ rearrangements.
Namely two different IGHV1-69/JH4 (V1-69-RF and WOL-RF)
rearrangements, IGHV3-7/JH3, IGHV4-59/JH2, and IGHV4-
59/JH5 rearrangements. The amino acid of the CDR3 of those
RF sequences is shown in Supplementary Table 3 where they are
compared to the homologous sequences from the pSS patients.
Because the presence of RF in serum of pSS patient was found
to be an independent predictor of non-Hodgkin’s Lymphoma,
including MALT lymphoma (29), we examined the presence
of RF encoding IGHV sequences in microdissected parotid
gland areas. We therefore compared the VH-CDR3 amino acid
sequence of our IGHV sequences for homology with VH-CDR3
amino acid sequence of known RFs, using the NCBI Protein-
BLAST algorithm (blastp; search for short nearly exact matches)
(19, 22). VH-CDR3 amino acids were considered homologs if
sharing at least 60% sequence homology and a length difference
between the CDR3 sequences of 3 amino acids or less (24).
Gene Expression Analysis by Quantitative
RT-PCR
Gene transcript expression levels of CD20 and FcRL4 (CD307d)
were measured with quantitative reverse transcription PCR (RT-
qPCR) using the CFX386 Real-Time PCR detection system and
Frontiers in Immunology | www.frontiersin.org 3 July 2020 | Volume 11 | Article 1486
Visser et al. Repertoire of B-Cells in pSS
reagents from BioRad (BioRad, Lunteren, The Netherlands).
ß-actin was used as housekeeping gene. In short, cDNA
and 150 nM primers (Supplementary Table 1) were diluted
in iQTMSYBR R©Green supermix to a final solution of 10 µl,
according to the manufacturer’s protocol. Each reaction was
performed in triplicate. A two-step cycling protocol was used
consisting of an initial denaturation/hot start step at 95◦C for
30 s, followed by 40 repetitive cycles of denaturing at 95◦C
for 15 s, annealing, and extension at 60◦C for 30 s. Finally, a
meltdown of the product from 60 to 95◦C with an increment
of 5◦C every 5 s was performed. The CFX manager software was
used to analyze the data. The relative gene expression of CD20
and FcRL4/CD307d was calculated using the double delta Ct
analysis (30).
Statistical Analysis
All statistical analyses were performed using GraphPad Prism
software (version 8.0). Statistical comparisons of data from
ductal and periductal derived IGHV sequences were carried out
using Wilcoxon matched-pairs signed rank test. P < 0.05 were
considered as statistical significant.
RESULTS
The total surface of the microdissected areas per patient ranged
from 28 to 54 µm2 for striated ducts and 23 to 56 µm2 for
periductal infiltrates. Virtually all B-cells in the striated ducts
express FcRL4, whereas the number of FcRL4+ B-cells in the
periductal areas is much lower (15). To confirm that FcRL4+ B-
cells are indeed strongly enriched in the microdissected striated
ducts, we performed RT-qPCR for relative levels of FcRL4
transcripts. mRNA transcripts from ducts and infiltrate were
amplified for both CD20 and FcRL4 and quantified using the
double delta Ct method. By calculating the ratio FcRL4/CD20
gene expression, we found up to 5-fold more FcRL4 expression
in the striated ducts compared to the periductal infiltrates
(Supplementary Figure 1).
VH-Gene Family Usage of Intraductal
B-Cells Is Similar to That of Periductal
B-Cells
Since the number of B-cells within the microdissected areas,
in particular in striated ducts, is relatively low, we analyzed
IGHV genes after cloning IGHV transcripts into appropriate
vectors, rather than by deep sequencing. A total of 214 unique
IGHV sequences was collected from microdissected areas of five
pSS parotid biopsies. Of these sequences, 96 unique intraductal
IGHV sequences were obtained from microdissected striated
ducts (15–33 IGHV sequences per patient), and 118 unique
periductal IGHV sequences from microdissected periductal
infiltrates (16–37 IGHV sequences per patient). IGHV sequences
from both microdissected ducts and infiltrates represented most
of the VH-gene families. The majority of IGHV genes derived
from both the microdissected striated ducts and periductal
infiltrates were encoded by VH1 genes (64 and 76%, respectively),
followed by VH3 genes (19 and 13%), and VH4 genes (17
and 6%). No other IGHV gene families were used by B-
cells within the striated ducts, whereas within the periductal
infiltrates, 5% of the IGHV genes were encoded by VH5
family genes (Figure 1, Supplementary Table 2). There were
a few dominant IGVH-genes present in both ductal and
periductal derived IGHV sequences. In both regions, IGHV1-69
and IGHV1-18 were most abundantly used (Table 2, Figure 2
and Supplementary Table 2). Although the usage of IGHV1-
69 seems to be 2-fold higher in periducts, this is most likely
due to a large VH1-69 clone in pSS2 that comprises 95%
of all periductal IGHV sequences from this patient (Table 3).
Among the VH3-genes, IGHV3-23 was most frequently present
in the striated ducts, especially in pSS4. In this patient, more
than 90% of the intraductal IGHV sequences were encoded by
VH3 family genes. In pSS4 particularly VH3-23 was strongly
(∼73%) overrepresented in the striated ducts compared with all
other ductal and periductal derived IGHV sequences. Of note,
this patient did not exhibit LELs in the parotid salivary gland,
which may possibly account for a relative low number of IGHV
sequences collected from the striated ducts and possibly also
FIGURE 1 | Frequency of VH-gene usage by intraductal and periductal B-cells. The IGHV genes of B-cells present in microdissected areas were sequenced and
analyzed by IMGT/V-QUEST for VH-gene repertoire usage.
Frontiers in Immunology | www.frontiersin.org 4 July 2020 | Volume 11 | Article 1486
Visser et al. Repertoire of B-Cells in pSS
TABLE 2 | Frequency of VH-gene usage of all IGHV sequences derived from
ductal and periductal areas.





























a different intraductal IGHV gene repertoire, compared to the
other patients (12).
The Vast Majority of Intraductal and
Periductal B-Cells Carry Mutated IGHV
Genes
IGHV sequences with a VH-gene≤1 nucleotide difference to the
nearest reference VH germline gene were considered as germline
sequences. Mutational analysis of the IGHV transcripts derived
from both intraductal and periductal B-cells present in parotid
gland biopsies, revealed only a very low (<10%) number of
germline sequences. In the pool of IGHV sequences derived
from the ducts, we observed five out of 96 germline sequences
(5%) (Supplementary Table 2). All these germline sequences
originated from one patient (pSS1). In the pool of IGHV
sequences derived from the periductal infiltrate, we observed
a similar low proportion of germline sequences: 10 out of 118
sequences (8%) were in germline configuration. These germline
sequences originated from 3 pSS patients (pSS1, pSS2, and
pSS4) (Supplementary Table 2). The low frequency of germline
encoded IGHV transcripts reflects the presence of relatively low
numbers of naïve B-cells and high numbers ofmemory (mutated)
B-cells, in parotid gland tissue of pSS patients (24).
Next, we analyzed the mutation frequency of the mutated
IGHV sequences (>1 nucleotide difference to closest reference
germline gene). To examine whether there is a difference in
mutation incidence between intraductal and periductal B-cells,
the mutation frequencies of all ductal derived IGHV sequences
were compared to all periductal derived IGHV sequences. To
prevent bias due to expanded clones, clonally related IGHV
sequences were counted as one. For this assessment, the mean
mutation frequency of all members of a particular clone were
taken. As we show in Figure 3, there was no significant
difference in mutation frequency observed in intraductal
derived IGHV sequences compared to periductal derived IGHV
sequences (P = 0.3529).
Both Striated Ducts and Periductal Areas
Comprise B-Cell Clones
To examine the presence of clonal expansions among B-
cells located in the striated ducts and/or periductal areas, and
to find possible relationships between B-cells at these two
sites, we searched for the presence of clonally related IGHV
sequences in the microdissected areas. IGHV sequences were
defined clonally related when they use the same VH-gene, share
mutations within the VH-gene and share near-identical amino
acid sequences encoded by the H-CDR3 region. Despite the
relative low number of IGHV sequences obtained per patient
we were able to detect many clonally related sequences both
derived from intraductal and periductal B-cells. Clonally related
sequences were observed in all patients (Table 3). In total 32
clones were found. Of all sequences analyzed, 138 sequences
(i.e., 57%) belonged to a clone. Out of 32 clones, 28 clones
shared identical VH-CDR3 amino acid sequences and four
shared near-identical VH-CDR3 regions with up to 4 amino
acid difference from each other (Supplementary Table 2). Of
these 32 clones, 12 clones were observed among sequences
derived from the microdissected ducts and 15 clones from the
periductal infiltrates. Interestingly, five clones were composed
of sequences derived from microdissected ducts and periductal
infiltrates. These shared clones were found in parotid gland tissue
of all pSS patients, except for pSS4. Most periductal sequences
from patient pSS2 belonged to one large clone. Although
this observation might be suggestive for MALT lymphoma,
this patient was not diagnosed histopathologically with such a
lymphoma. Recent visit to our clinic also showed no indication
for MALT development.
VH-gene analysis of all clones showed that most clones
(∼73%) were of VH1 origin followed by VH3 (12%), VH4 (12%),
and VH5 (3%) (Table 3), which roughly reflects the proportion
of the various VH-gene families expressed in the biopsies.
Accordingly, most of the clones expressing VH1 sequences were
encoded by the IGHV1-69 gene (38% of total number of VH1
clones) followed by IGHV1-18 (29%), IGHV1-8 (17%), and
IGHV1-2 (17%).
B-Cell Receptors of Intraductal B-Cells
and Periductal B-Cells Occasionally
Express RF
Since MALT lymphomas may arise from B-cells associated with
striated ducts (15) and neoplastic MALT B-cells frequently
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FIGURE 2 | Frequency of VH-gene usage by intraductal and periductal B-cells per pSS patient. The IGHV genes of B-cells present in microdissected areas were
sequenced and analyzed by IMGT/V-QUEST for VH-gene repertoire usage.
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TABLE 3 | Summary of characteristics of clones found in microdissected striated
ducts and periductal infiltrates from parotid salivary gland biopsies per pSS
patient.
Patient Clone VH-gene JH-gene Origin of IGHV sequence
(number of clonally related
sequences)
Ductal areas Periductal areas
pSS1 1 IGHV1-18 IGHJ4 5
pSS1 2 IGHV1-69 IGHJ5 2
pSS1 3 IGHV1-8 IGHJ4 2 1
pSS1 4 IGHV1-18 IGHJ4 4
pSS1 5 IGHV1-2 IGHJ6 3
pSS1 6 IGHV1-69 IGHJ2 2
pSS1 7 IGHV5-51 IGHJ2 2
pSS2 8 IGHV1-18 IGHJ5 3
pSS2 9 IGHV1-69 IGHJ3 4 34
pSS2 10 IGHV4-59 IGHJ6 6
pSS3 11 IGHV1-18 IGHJ6 5
pSS3 12 IGHV1-18 IGHJ6 2
pSS3 13 IGHV1-8 IGHJ4 5 2
pSS3 14 IGHV4-59 IGHJ5 5 1
pSS3 15 IGHV1-8 IGHJ4 3
pSS3 16 IGHV1-2 IGHJ4 2
pSS4 17 IGHV3-21 IGHJ4 2
pSS4 18 IGHV3-23 IGHJ5 6
pSS4 19 IGHV3-23 IGHJ4 2
pSS4 20 IGHV1-18 IGHJ5 2
pSS4 21 IGHV3-15 IGHJ4 2
pSS4 22 IGHV4-39 IGHJ3 2
pSS4 23 IGHV4-39 IGHJ4 2
pSS5 24 IGHV1-2 IGHJ3 2
pSS5 25 IGHV1-2 IGHJ4 2
pSS5 26 IGHV1-69 IGHJ4 7
pSS5 27* IGHV1-69 IGHJ4 1 4
pSS5 28 IGHV1-69 IGHJ4 2
pSS5 29 IGHV1-69 IGHJ4 2
pSS5 30 IGHV1-69 IGHJ4 2
pSS5 31 IGHV1-69 IGHJ6 3
pSS5 32 IGHV1-8 IGHJ6 2
*Clone with IGHV sequences with CDR3-RF homology.
express RF (19), we analyzed whether non-malignant intraductal
and/or periductal B-cells are enriched in IGHV genes encoding
for immunoglobulins with RF activity. We therefore compared
VH-CDR3 amino acid sequences of all IGHV sequences for
CDR3-RF homology (Supplementary Table 3). Of note, all
patients, except for pSS4, were tested seropositive for RF
(Table 1). IGHV sequences with VH-CDR3 regions showing
homology for CDR3-RF regions were present among IGHV
sequences from four out of five patients. In line with the
serum data, no RF sequences were observed in patient 4.
Only two out of 96 IGHV sequences (2%) derived from B-
cells located in the striated duct and 10 out of 118 IGHV
FIGURE 3 | Mutation frequency of all IGHV sequences in striated ducts
compared to periductal infiltrates. The nucleotide sequences of the IGHV
sequences were aligned to the closest VH-REGION alleles from the
IMGT/V-QUEST reference directory sets. The mutation frequency was
calculated as 100% minus the % of nucleotide identity. Each dot or square
represents an IGHV sequence, the horizontal bars show the median.
sequences (8%) in the periductal infiltrate were homologs to
CDR3-RF. Remarkedly, 11 (one intraductal and 10 periductal)
IGHV sequences with CDR3-RF homology, were encoded by
VH/JH rearrangements characteristic for stereotypic RFs (19, 22)
(Supplementary Table 3).
Among the total of 12 IGHV sequences with CDR3-RF
homology, 9 (75%) sequences were derived from the parotid
biopsy of only one patient, pSS5. These sequences were part of
three clones with respectively 5, 2, and 2 members. When the RF
sequences that originate from one clone are counted as one, the
frequency of RF sequences in the periductal infiltrate becomes
5/118 (4%). Of the largest clone one member was of ductal origin
and the remaining four were from the periductal region. The
members of the other two clones were all from periductal origin
(Table 2). Together, the data indicate that intraductal B-cells are
not enriched in B-cells expressing a BCR exhibiting RF specificity.
DISCUSSION
B-cell hyperactivity is a hallmark of pSS, which may culminate in
the formation of MALT lymphomas, which frequently develop
within the parotid salivary gland. B-cells located within the
striated ducts may be the cells from which the neoplastic
B-cells arise (15). These intraductal B-cells are also held
responsible for the formation of lymphoepithelial lesions (12),
which are critically involved in MALT lymphomagenesis. MALT
lymphoma B-cells in pSS parotid glands frequently exhibit
RF specificity (19, 20). For this reason we explored whether
intraductal B-cells are selected on the basis of specificity of the
BCR. Here we observed that there are no major differences in
the IGHV gene repertoire of intraductal B-cells and of periductal
B-cells. At both locations the vast majority (>90%) of B-cells
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express mutated IGHV genes, indicating that nearly all cells
represent memory cells. Importantly, B-cells expressing VH-
CDR3 regions, encoding for RF specificity, are not enriched in
striated ducts. An important finding was that a large fraction
(57%) of IGHV sequences were clonally related to each other.
These sequences were derived from B-cell clones with members
either only in the ducts or only in the periductal areas, and
importantly, also from clones with members in the ducts and in
the periductal areas. Taken together, the data indicate that there is
a significant exchange of B-cells located in the striated ducts and
B-cells in the periductal region and that recruitment of B-cells
into the ducts is most likely not driven by their BCR specificity.
Nearly all, if not all, B-cells located in the striated ducts
express FcRL4 (15). Transcriptomic analysis and phenotypic
characterization of tonsillar FcRL4+ B-cells and FcRL4+ B-cells
in synovial tissue of patients with rheumatoid arthritis indicate
that FcRL4+ B-cells are pro-inflammatory, activated, memory
cells (31, 32). We recently confirmed this also for FcRL4+ B-
cells in parotid salivary glands of pSS patients (16). Parotid
FcRL4+ B-cells of pSS patients show gene expression profile
with similarities to chronically activated CD11c+T-bet+ memory
B-cells which are involved in the pathogenesis of systemic
lupus erythematosus (18, 33). These findings also revealed that
these glandular FcRL4+ B-cells express the chemokine receptor
CXCR3. CXCR3 can bind to the interferon-induced chemokine
CXCL10/IP-10, which is produced in large quantities by ductal
epithelial cells in the salivary glands of pSS patients (34). Any
activated B-cell, expressing FcRL4 and CXCR3, located in the
periductal area can likely be attracted to migrate into the
striated ducts by CXCL10, irrespective of the antigen specificity
of the B-cell. Once arrived in the striated ducts the (already)
activated B-cells may be activated further, possibly supported
by cytokines secreted by ductal epithelial cells. The ducts in
the pSS salivary glands secrete a wide variety of cytokines that
support B-cell activation (35). These cytokines include BAFF and
APRIL which can bind to their receptor TACI. This receptor
is upregulated in FcRL4+ B-cells, and binding of BAFF/APRIL
results in enhanced NF-kB mediated B-cell activation (36, 37).
Indeed, FcRL4+ intraductal B-cells proliferate highly and ∼15–
20% of the cells in labial and parotid salivary glands of pSS
patients are actively dividing as witnessed by their expression
of Ki-67 (15). This expansion is also mirrored by the presence
of intraductal B-cell clones, which we identified based on IGHV
gene analysis. Clonal expansion is, however, clearly not restricted
to the ducts, as periductal B-cell clones are also seen. During B-
cell activation and clonal expansion some intraductal (activated)
B-cells may leave again the striated ducts toward the periductal
areas. The intimate relationship between B-cells located within
the striated ducts and B-cells present in the periductal infiltrates
is underscored by the presence of B-cell clones, with members
located at both sites. Since most MALT lymphomas consist of
IgM producing cells (19, 20), we have confirmed the presence
of IgM, IgG, and IgA producing B-cells in the ductal areas
(Supplementary Figure 2). We could confirm this further by
analyzing FcRL4+ B-cells sorted from parotid glands by RNA-
seq. We found transcripts for IgM as well as IgG and IgA (data
not shown).
During humoral immune responses, somatic hypermutation
of V-genes associated with selection of memory cells with
high affinity BCRs, usually takes place within the germinal
centers. Cumulating evidence, however, shows this somatic
hypermutation process can also occur outside germinal centers,
in particular in autoimmune disease (8, 24, 38, 39). In the
salivary gland biopsies of the pSS patients, there was no
evidence for the presence of ectopic germinal centers in the
tertiary lymphoid tissue, although we cannot formally rule out
the possibility that elsewhere in the parotid gland germinal
centers might be present. The observed local clonal expansions
of both intraductal and periductal B-cells associated with the
accumulation of somatic mutations, thus most probably occur
independent from germinal centers. FcRL4+ B-cells, including
FcRL4+ B-cells within the salivary glands of pSS patient, have
the potency to express activation-induced-deaminase (AID), an
enzyme critically involved in somatic hypermutation (15, 16,
31, 40, 41). The proliferative activity, expression of AID, and
the association with lymphoepithelial lesions, characteristic for
MALT lymphomas, may make the intraductal B-cells prone for
neoplastic derailment.
Presence of RF in serum of pSS patients is an independent
predictor for (MALT) lymphoma development (29). The
majority, if not all MALT lymphomas in salivary glands of pSS
patients are composed of B-cells with a BCR with RF specificity
(19, 21). These BCRs are mostly encoded by stereotypic CDR3-
RF sequences (19, 20). RF sequences were only found in those
patients that expressed RF in the serum. We observed that only
2% of the intraductal B-cells express RF- BCRs compared to 4–
8% of the periductal B-cells, depending on whether you take
the clones into consideration. The higher frequency of CDR3-
RFs in the periductal areas was mainly due to presence of three
RF-clones in the parotid biopsy of pSS5. Interestingly, one of
the B-cell clones with members in the striated ducts and in
the periductal region exhibited RF reactivity by expressing a
BCR encoded by VH-CDR3 with homology for the stereotypic
IGHV1-69-RF found in salivary gland MALT lymphoma as
described by Miklos et al. (42). During follow- up of this patient
for 9 years, this patient has not developed a MALT lymphoma.
Importantly, intraductal B-cells, as well as periductal B-cells,
show a low frequency of B-cells with RF-specificity. Also, most of
the clones did not express BCRs with homology for (stereotypic)
RF sequences, indicating that clonal expansion is not dependent
of a BCR with RF specificity. Since more than 40% of the pSS
associated glandular MALT lymphomas express RF, expression
of RF by a B-cells is apparently an important risk factor for
neoplastic transformation of B-cells towardMALT lymphoma. B-
cells expressing BCRs with RF specificity may be extra stimulated
in an environment with immune complexes binding to the
RF and nucleoprotein autoantigens (SSA and SSB) binding to
e.g., toll-like receptors. The stimulatory environment of the
striated ducts as a source of both B-cell activating cytokines
and SSA/B autoantigens may contribute to the preferential
activation and proliferation of the intraductal B-cells once
attracted to the striated ducts. The expression of AID by FcRL4+
intraductal B-cells may further contribute in derailment toward
MALT lymphomas, by mutating non-immunoglobulin genes
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(43). Further support for this hypothesis comes from a recent
study of Singh et al. (44). They showed that in pSS patients,
pathogenic RF-expressing B-cells are formed exclusively in RF-
expressing cells after acquiring lymphoma driver mutations.
Apparently, RF-specificity is required for the pathogenic and
neoplastic transformation of the cells.
To conclude, it is unlikely that RF specific B-cells are
preferentially recruited from the periductal regions into the
striated ducts in the salivary glands of patients with pSS. Instead,
we postulate that in principle any activated B-cell can migrate
into the striated ducts, irrespective of its BCR specificity. The
high frequency of MALT lymphomas expressing BCRs with RF-
specificity suggests that this may be an important risk factor
toward MALT lymphoma development, in particular in the
stimulatory microenvironment of the striated duct.
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